Toxicity of Cetuximab, Paclitaxel, Cisplatin and Concurrent Radiation in Chinese Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: An Open-label, Multicenter Phase II Study

被引：0
|
作者：
Yu, J. [1 ]
Wang, J. [2 ]
Sun, X. [1 ]
Wang, L. [3 ]
Ye, M. [4 ]
Feng, P. [5 ]
Zhu, G. [6 ]
Lu, Y. [7 ]
Zhu, S. [8 ]
Liao, Z. [9 ]
机构：
[1] Shandong Canc Hosp, Jinan 250117, Shandong, Peoples R China
[2] Zhengzhou Univ, Canc Hosp, Jinan 250117, Shandong, Peoples R China
[3] Chinese Acad Med Sci, Peking Union Med Coll, Canc Hosp, Beijing 100730, Peoples R China
[4] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai 200030, Peoples R China
[5] Jiangsu Canc Hosp, Nanjing, Peoples R China
[6] Peking Univ, Sch Oncol, Beijing Canc Hosp, Beijing 100871, Peoples R China
[7] Sichuan Univ, W China Hosp, W China Sch Med, Chengdu 610064, Peoples R China
[8] Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China
[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2011年 / 81卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2011.06.512
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S315 / S316
页数：2
相关论文
共 50 条
  • [1] Cetuximab, paclitaxel, cisplatin and concurrent radiation in Chinese patients with locally advanced esophageal squamous cell carcinoma: An open-label, multicenter, phase II study.
    Yu, Jinming
    Meng, Xue
    Wang, Jian Hua
    Sun, Xindong
    Wang, Lv Hua
    Ye, Ming
    Feng, Ping Bo
    Zhu, Guang Ying
    Lu, You
    Han, Chun
    Zhu, Shu Chai
    Liao, Zhongxing X.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] KRAS mutation status and toxicity of cetuximab, paclitaxel, cisplatin, and concurrent radiation in Chinese patients with locally advanced esophageal squamous cell carcinoma: An open-label, multicenter, phase II study.
    Yu, J.
    Meng, X.
    Wang, J. H.
    Sun, X.
    Wang, L.
    Ye, M.
    Feng, P. B.
    Zhu, G. Y.
    Lu, Y.
    Zhu, S. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] An open label, multicenter clinical study of cetuximab combined with concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma Preliminary results of a phase II trial
    Yu, J. M.
    Wang, J. H.
    Sun, X.
    Wang, L. H.
    Zhu, G. Y.
    Feng, P. B.
    Ye, M.
    Lu, Y.
    Zhu, S. C.
    Liao, Z. X.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] An Open Label, Multicenter Clinical Study of Cetuximab Combined with Concurrent Chemo-radiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: Preliminary Results of a Phase II Trial
    Yu, J.
    Wang, J. H.
    Sun, X. D.
    Wang, L. H.
    Zhu, G. Y.
    Feng, P. B.
    Ye, M.
    Lu, Y.
    Zhu, S. C.
    Liao, Z. X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (03): : S309 - S309
  • [5] Cetuximab combined with concurrent chemoradiotheray in Chinese patients with unresectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trial.
    Meng, Xue
    Wang, Jianhua
    Sun, Xindong
    Wang, Lvhua
    Ye, Ming
    Feng, Ping Bo
    Zhu, Guangying
    Lu, You
    Han, Chun
    Zhu, Shu Chai
    Liao, Zhongxing X.
    Yu, Jinming
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial
    Lu, Zhihao
    Zhang, Yanqiao
    Fan, Qingxia
    Pan, Yueyin
    Jiang, Da
    Lu, Ping
    Zhang, Jingdong
    Yuan, Xianglin
    Feng, Jifeng
    Yang, Shujun
    Yue, Wenbin
    Zhao, Lin
    Xu, Yunhua
    Luo, Jinhua
    Shen, Lin
    INNOVATION, 2022, 3 (03):
  • [7] A Phase I/II Study of Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Squamous Cell Cancer of the Head and Neck
    Chun, Stephen G.
    Hughes, Randall
    Sumer, Baran D.
    Myers, Larry L.
    Truelson, John M.
    Khan, Saad A.
    Ma, Tsung-Wei
    Xie, Yang
    Yordy, John S.
    Cooley, Susan
    Wu, Jean
    Choy, Hak
    Nedzi, Lucien A.
    CANCER INVESTIGATION, 2017, 35 (01) : 23 - 31
  • [8] Concurrent chemoradiotherapy with cetuximab plus twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma
    Hsu, C.
    Lin, C.
    Cheong, J. C.
    Yen, C.
    Lee, J.
    Wang, H.
    Yeh, K.
    Cheng, A.
    Lee, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] A Phase II Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin for Inoperable Esophageal Squamous Cell Carcinoma
    Tang, Hua-Rong
    Ma, Hai-Feng
    An, Shi-Min
    Badakhshi, Harun
    Deng, Jia-Ying
    Zhang, Jun-Hua
    Chen, Yun
    Zhang, Zhen
    Guo, Xiao-Mao
    Jiang, Guo-Liang
    Zhao, Kuai-Le
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (04): : 350 - 354
  • [10] Concurrent chemoradiotherapy with cetuximab plus twice-weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal squamous cell carcinoma
    Lin, C.
    Hsu, C.
    Cheng, J. C.
    Yen, C.
    Shiah, H.
    Lee, J.
    Wang, H.
    Yeh, K.
    Cheng, A.
    Lee, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345